Jennifer H Anolik

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3089606/jennifer-h-anolik-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88 6,584 81 40 h-index g-index citations papers 8,067 5.46 109 7.3 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
88	Dynamic spectrum of ectopic lymphoid B cell activation and hypermutation in the RA synovium characterized by NR4A nuclear receptor expression <i>Cell Reports</i> , 2022 , 39, 110766	10.6	1
87	B Cell Activation and Plasma Cell Differentiation Are Promoted by IFN-lin Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2021 , 207, 2660-2672	5.3	1
86	Urine Proteomics and Renal Single Cell Transcriptomics Implicate IL-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	1
85	B-cell biology, tolerance, and autoantibodies 2021 , 71-80		
84	Activated peripheral blood B cells in rheumatoid arthritis and relationship to anti-TNF treatment and response: randomized clinical trial for anti-TNF effects on B cells. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	6
83	IFN signaling inhibits osteogenesis in human SLE bone marrow. <i>Lupus</i> , 2020 , 29, 1040-1049	2.6	5
82	Autoreactivity in nalle human fetal B cells is associated with commensal bacteria recognition. <i>Science</i> , 2020 , 369, 320-325	33.3	15
81	Bone marrow mesenchymal stem cells from patients with SLE maintain an interferon signature during in vitro culture. <i>Cytokine</i> , 2020 , 132, 154725	4	4
80	Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 553-555	2.4	1
79	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019 , 20, 902-914	19.1	254
78	Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN. <i>Journal of Autoimmunity</i> , 2019 , 102, 150-158	15.5	17
77	Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. <i>Nature Immunology</i> , 2019 , 20, 928-942	19.1	369
76	PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. <i>JCI Insight</i> , 2019 , 4,	9.9	76
75	B cell targeted therapies in autoimmune disease. Current Opinion in Immunology, 2019, 61, 92-99	7.8	32
74	Impaired ATM activation in B cells is associated with bone resorption in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	12
73	Failure of B Cell Tolerance in CVID. Frontiers in Immunology, 2019, 10, 2881	8.4	7
72	Cell Senescence in Lupus. Current Rheumatology Reports, 2019, 21, 1	4.9	5

(2014-2018)

71	Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus. <i>JCI Insight</i> , 2018 , 3,	9.9	32
7°	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. <i>Arthritis Research and Therapy</i> , 2018 , 20, 139	5.7	60
69	AI-19 T peripheral helper cells are expanded in the circulation of active SLE patients and correlate with CD21low B cells 2018 ,		2
68	B cells inhibit bone formation in rheumatoid arthritis by suppressing osteoblast differentiation. <i>Nature Communications</i> , 2018 , 9, 5127	17.4	61
67	Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. <i>Immunity</i> , 2018 , 49, 725-739.e6	32.3	303
66	PKK deficiency in B cells prevents lupus development in Sle lupus mice. <i>Immunology Letters</i> , 2017 , 185, 1-11	4.1	2
65	Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon-Feedback Loop. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1623-1635	9.5	39
64	Neutrophils Slow Disease Progression in Murine Lupus via Modulation of Autoreactive Germinal Centers. <i>Journal of Immunology</i> , 2017 , 199, 458-466	5.3	16
63	Production of RANKL by Memory B Cells: A Link Between B Cells and Bone Erosion in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 805-16	9.5	97
62	Inhibition of G Protein L Subunit Signaling Abrogates Nephritis in Lupus-Prone Mice. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2244-56	9.5	11
61	Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. <i>Journal of Proteome Research</i> , 2016 , 15, 2102-14	5.6	32
60	New insights into B cell biology in systemic lupus erythematosus and Sjgrenß syndrome. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 461-7	5.3	21
59	Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response. <i>PLoS ONE</i> , 2015 , 10, e0128269	3.7	91
58	Characterization of Small Molecule Glinhibitors in the Context of Inflammation. <i>FASEB Journal</i> , 2015 , 29, 618.4	0.9	
57	Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche. <i>Journal of Immunology</i> , 2014 , 192, 3011-20	5.3	22
56	Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. <i>Journal of Immunology</i> , 2014 , 192, 906-18	5.3	62
55	Primary Sjgrenß syndrome is characterized by distinct phenotypic and transcriptional profiles of IgD+ unswitched memory B cells. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2558-69	9.5	33
54	NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF- B . <i>Journal of Clinical Investigation</i> , 2014 , 124, 3200-14	15.9	53

53	B cell biology: implications for treatment of systemic lupus erythematosus. <i>Lupus</i> , 2013 , 22, 342-9	2.6	45
52	Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. <i>Arthritis and Rheumatism</i> , 2012 , 64, 493-503		185
51	Treatment targets in systemic lupus erythematosus: biology and clinical perspective. <i>Arthritis Research and Therapy</i> , 2012 , 14 Suppl 4, S3	5.7	18
50	Quantitative proteomics of parotid saliva in primary Sjgrenß syndrome. <i>Proteomics</i> , 2012 , 12, 3113-20	4.8	37
49	Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. <i>Arthritis Research and Therapy</i> , 2011 , 13, R209	5.7	58
48	B cell immunology for the clinician. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 158-60	3.4	1
47	Immunologic reconstitution after rituximab in systemic lupus erythematosus: why should we care?. <i>Journal of Rheumatology</i> , 2011 , 38, 587-9	4.1	3
46	A perspective on B-cell-targeting therapy for SLE. <i>Modern Rheumatology</i> , 2010 , 20, 1-10	3.3	27
45	B-cell biology and related therapies in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010 , 36, 109-30, viii-ix	2.4	18
44	B cells in the pathogenesis and treatment of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2010 , 22, 307-15	5.3	87
43	Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2443-57		80
42	A perspective on B-cell-targeting therapy for SLE. <i>Modern Rheumatology</i> , 2010 , 20, 1-10	3.3	19
41	Novel human transitional B cell populations revealed by B cell depletion therapy. <i>Journal of Immunology</i> , 2009 , 182, 5982-93	5.3	210
40	Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. <i>Immunologic Research</i> , 2009 , 45, 144-58	4.3	70
39	Two negative randomized controlled trials in lupus: now what?. F1000 Medicine Reports, 2009, 1,		1
38	A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. <i>Clinical Immunology</i> , 2008 , 126, 189-201	9	81
37	Phenotypic and functional heterogeneity of human memory B cells. <i>Seminars in Immunology</i> , 2008 , 20, 67-82	10.7	277
36	Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 425-7	5	56

(2004-2008)

35	Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. <i>Cancer Investigation</i> , 2008 , 26, 431-3	2.1	28
34	Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. <i>Journal of Immunology</i> , 2008 , 180, 688-92	5.3	121
33	Targeted biologic approaches to the treatment of systemic vasculitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2008 , 35, 79-87	12.3	2
32	Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3044-56		233
31	B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. <i>Clinical Immunology</i> , 2007 , 122, 139-45	9	137
30	Vaccine responses in patients with rheumatoid arthritis. Current Rheumatology Reports, 2007, 9, 407-15	4.9	14
29	A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. <i>Journal of Immunology</i> , 2007 , 178, 6624-33	5.3	374
28	B cell depletion therapy in autoimmune diseases. Frontiers in Bioscience - Landmark, 2007 , 12, 2546-67	2.8	54
27	B cell biology and dysfunction in SLE. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65, 182-6		45
26	New therapies for systemic lupus erythematosus: cellular targets. <i>Rheumatic Disease Clinics of North America</i> , 2006 , 32, 201-15, xi	2.4	14
25	B-cell-targeted therapy for systemic lupus erythematosus. <i>Drugs</i> , 2006 , 66, 1933-48	12.1	74
24	Reconstitution of the adult B cell repertoire after treatment with rituximab. <i>Arthritis Research and Therapy</i> , 2005 , 7, 175-6	5.7	16
23	Treatment of SLE with anti-CD20 monoclonal antibody. Current Directions in Autoimmunity, 2005, 8, 193	-205	32
22	New treatments for SLE: cell-depleting and anti-cytokine therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 859-78	5.3	71
21	Human innate B cells: a link between host defense and autoimmunity?. <i>Seminars in Immunopathology</i> , 2005 , 26, 433-52		51
20	Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2005 , 115, 3205-16	15.9	242
19	B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. <i>Lupus</i> , 2004 , 13, 381-90	2.6	50
18	B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2580-9		642

17	Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3580-90		365
16	From Cold-Agglutinin Disease to Systemic Lupus Erythematosus: Lessons in Human B-Cell Tolerance and Its Breakdown. <i>Transfusion Medicine and Hemotherapy</i> , 2004 , 31, 84-90	4.2	3
15	B cells in human and murine systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 505-12	5.3	37
14	Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. <i>Journal of Immunology</i> , 2004 , 172, 4298-307	5.3	188
13	B cells as therapeutic targets for rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 180-5	5.3	86
12	B cell depletion therapy in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2003 , 5, 350-6	4.9	53
11	Down-regulation of CD20 on B cells upon CD40 activation. <i>European Journal of Immunology</i> , 2003 , 33, 2398-409	6.1	46
10	The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003 , 48, 455-9		375
9	Posttransfusion purpura secondary to an alloantibody reactive with HPA-5a (Br(b)). <i>Transfusion</i> , 2001 , 41, 633-6	2.9	15
8	Effects of multiple estrogen responsive elements, their spacing, and location on estrogen response of reporter genes. <i>Molecular Endocrinology</i> , 1997 , 11, 1994-2003		58
7	Stability of the ligand-estrogen receptor interaction depends on estrogen response element flanking sequences and cellular factors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1996 , 59, 413-29	5.1	30
6	Cooperative binding of estrogen receptor to DNA depends on spacing of binding sites, flanking sequence, and ligand. <i>Biochemistry</i> , 1995 , 34, 2511-20	3.2	46
5	Differential impact of flanking sequences on estradiol- vs 4-hydroxytamoxifen-liganded estrogen receptor binding to estrogen responsive element DNA. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993 , 46, 713-30	5.1	29
4	A protocol for single-cell transcriptomics from cryopreserved renal tissue and urine for the Accelerating Medicine Partnership (AMP) RA/SLE network		11
3	High dimensional analyses of cells dissociated from cryopreserved synovial tissue		2
2	Defining Inflammatory Cell States in Rheumatoid Arthritis Joint Synovial Tissues by Integrating Single-cell Transcriptomics and Mass Cytometry		3
1	Single cell analysis of RA synovial B cells reveals a dynamic spectrum of ectopic lymphoid B cell activation and hypermutation characterized by NR4A nuclear receptor expression		1